FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164172015> ?p ?o ?g. }

• W3164172015 endingPage "500" @default.
• W3164172015 startingPage "499" @default.
• W3164172015 abstract "Background: It is not well understood why hypertension (HTN) is so common in rheumatoid arthritis (RA) patients. Reported prevalence of HTN in RA patients ranges from 4-73%.(1) Objectives: This study explored the prevalence of HTN at time of RA diagnosis and which demographic, behavioural and clinical factors were associated with HTN. Methods: Data from the Canadian Early Arthritis Cohort (CATCH), a prospective inception cohort of patients with RA <1 year duration, were used to analyze baseline demographic, behavioural and clinical characteristics associated with HTN, which was reported by physicians. Univariate logistic regression models were created to explore associations with baseline HTN. A multivariate logistic regression model was built based on goodness of fit indicated by likelihood ratio tests. Variables included in the model were age, sex, race, body mass index (BMI), education, smoking, alcohol servings, seropositivity, disease activity and comorbidities. Results: In total, 2052 subjects were included with mean (±SD) age of 55 (±14) years and symptom duration 5.60(5.47, 5.73) months, 71% of subjects were female and 85% were Caucasian. HTN was reported in 26% of subjects at baseline. Hypertensive subjects were older and more likely to be male. Other factors significantly associated with HTN at baseline were lower education, ever smoking, high BMI, diabetes, hyperlipidemia, worse RA disease activity, longer duration of RA symptoms, being seropositive, as well as the use of NSAIDs and/or corticosteroids (Table 1). In multivariable analysis HTN was associated with older age, overweight and obese BMI, diabetes, and hyperlipidemia. Expression of anti-citrullinated protein antibodies was inversely associated with HTN (Table 1). Other RA disease factors and treatments were not significantly associated with HTN on multivariable analysis. Table 1. Results of univariate and multivariate logistic regression analyses exploring the association between baseline characteristics and HTN in early RA. Univariate Logistic Regression Multivariable Logistic Regression Variable Crude OR (95% CI ) Adjusted OR (95% CI ) Socio-Demographic 20-39 years old 0.15 (0.07, 0.26) 0.14(0.05, 0.34) 40-59 years old Reference 60-79 years old 2.81 (2.26, 3.50) 2.26(1.65, 3.11) 80-99 years old 5.87 (3.36,10.25) 3.80(1.53, 9.41) Female 0.55 (0.45, 0.68) 1.10(0.78, 1.54) Lifestyle/Behavioural Normal weight (18.5- 24.9kg/m 2 ) Reference Overweight (25-29.9 kg/m 2 ) 2.33(1.74, 3.11) 1.63(1.10, 2.43) Obese (30+ kg/m 2 ) 3.19(2.38, 4.27) 2.84(1.91, 4.23 Ever-smoking 1.41(1.15, 1.73) 1.02(0.75, 1.40) Post-secondary education 0.58(0.47, 0.71) 0.88(0.65, 1.20) Clinical Characteristics Symptom duration 0.99(0.99, 0.99) 1.00(1.00, 1.00) DAS-28 1.09(1.09, 1.17) 1.02(0.92, 1.13) ACPA+ 0.68(0.56, 0.85) 0.64(0.44, 0.92) Corticosteroid use pre-baseline 1.37(1.04, 1.81) Omitted NSAID use at baseline 0.68(0.55, 0.84) Omitted Diabetes 5.62(4.09, 7.73) 3.20(1.99, 5.15) Hyperlipidemia 4.75(3.74, 6.03) 2.80(1.94, 4.02), CVD 15.59(3.35, 72.64) Omitted DAS-28; Disease activity score 28, ACPA; Anti-citrullinated protein antibody, CVD; Cardiovascular disease. Pre-baseline is 29 to 365 days before entering the cohort. Baseline is within 28 days before entering the cohort. Omitted variables either failed likelihood ratio test or were colinear. Additional variables tested but found insignificant: race, alcohol servings, depression, RF+, and use of DMARDs. Conclusion: Approximately 1 in 4 diagnosed with RA had HTN reported by their rheumatologists, which is similar to that of the general population. This suggests that increased risk of HTN in RA patients may develop as RA disease or treatment time progresses. Factors that may be predictive of this excess risk will be explored in further analysis. References: [1]Panoulas VF, Metsios GS, Pace AV, et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford ) 2008;47:1286-98. Acknowledgements: The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation and Hoffmann-LaRoche since 2011; Medexus Inc. since 2013;, Merck Canada since 2017, Sandoz Canada, Biopharmaceuticals since 2019,Gilead Sciences Canada since 2020 and Fresenius Kabi Canada Ltd. since 2021. Previously funded by Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squibb Canada from 2011-2018, Sanofi Genzyme from 2016-2017, and Eli Lilly Canada from 2016-2020. Disclosure of Interests: Brook Hadwen: None declared, Saverio Stranges: None declared, Neil Klar: None declared, Kuriya Bindee: None declared, Janet Pope Speakers bureau: UCB, Consultant of: AbbVie, Actelion, Amgen, Bayer, BMS, Eicos Sciences, Eli Lilly & Company, Emerald, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB;, Grant/research support from: Abbvie, BMS, Eli Lilly & Company, Merck, Roche, Seattle Genetics, UCB, Susan J. Bartlett Consultant of: Pfizer, UCB, Lilly, Novartis, Merck, Janssen, Abbvie, Gilles Boire Speakers bureau: Merck, BMS, Pfizer, Janssen, Grant/research support from: Amgen, Abbvie, BMS, Eli Lilly, Merck, Novartis, Pfizer, Sandoz, Louis Bessette Speakers bureau: Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis, Consultant of: Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis., Grant/research support from: Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis., Carol Hitchon Grant/research support from: Pfizer and UCB Canada, Glen Hazlewood: None declared, Edward Keystone Speakers bureau: Amgen, AbbVie, Bristol-Myers Squibb, F. Hoffmann-La Roche Inc., Janssen Inc., Merck, Pfizer Pharmaceuticals, Sanofi Genzyme, UCB, Consultant of:: AbbVie, Amgen, AstraZeneca Pharma, Bristol-Myers Squibb Company, Celltrion, Myriad Autoimmune, F. Hoffmann-La Roche Inc, Genentech Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, Sandoz, Sanofi-Genzyme, Samsung Bioepsis, Grant/research support from: AbbVie, Amgen, Gilead Sciences, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, PuraPharm, Sanofi, Orit Schieir: None declared, Carter Thorne Speakers bureau: Medexus/Medac, Consultant of: Abbvie, Centocor, Janssen, Lilly, Medexus/Medac, Pfizer, Grant/research support from: Amgen, Pfizer, Abbvie, Celgene, CaREBiodam, Novartis, Diane Tin: None declared, Marie-France Valois: None declared, Vivian Bykerk Consultant of: Amgen, BMS, Gilead, Sanofi-Genzyme/Regeneron, Scipher, Pfizer Pharmaceuticals, UCB, NIH, Lillian Barra: None declared" @default.
• W3164172015 created "2021-06-07" @default.
• W3164172015 creator A5010655048 @default.
• W3164172015 creator A5010734100 @default.
• W3164172015 creator A5018840766 @default.
• W3164172015 creator A5019224959 @default.
• W3164172015 creator A5022795665 @default.
• W3164172015 creator A5023213876 @default.
• W3164172015 creator A5023988126 @default.
• W3164172015 creator A5027044264 @default.
• W3164172015 creator A5034266471 @default.
• W3164172015 creator A5045325872 @default.
• W3164172015 creator A5054685224 @default.
• W3164172015 creator A5055302708 @default.
• W3164172015 creator A5061139474 @default.
• W3164172015 creator A5073627317 @default.
• W3164172015 creator A5079550885 @default.
• W3164172015 creator A5079946212 @default.
• W3164172015 creator A5080646462 @default.
• W3164172015 date "2021-05-19" @default.
• W3164172015 modified "2023-10-18" @default.
• W3164172015 title "POS0531 FACTORS ASSOCIATED WITH BASELINE HYPERTENSION IN EARLY RHEUMATOID ARTHRITIS: DATA FROM A REAL-WORLD LARGE INCIDENT COHORT" @default.
• W3164172015 cites W2142177680 @default.
• W3164172015 doi "https://doi.org/10.1136/annrheumdis-2021-eular.1835" @default.
• W3164172015 hasPublicationYear "2021" @default.
• W3164172015 type Work @default.
• W3164172015 sameAs 3164172015 @default.
• W3164172015 citedByCount "0" @default.
• W3164172015 crossrefType "journal-article" @default.
• W3164172015 hasAuthorship W3164172015A5010655048 @default.
• W3164172015 hasAuthorship W3164172015A5010734100 @default.
• W3164172015 hasAuthorship W3164172015A5018840766 @default.
• W3164172015 hasAuthorship W3164172015A5019224959 @default.
• W3164172015 hasAuthorship W3164172015A5022795665 @default.
• W3164172015 hasAuthorship W3164172015A5023213876 @default.
• W3164172015 hasAuthorship W3164172015A5023988126 @default.
• W3164172015 hasAuthorship W3164172015A5027044264 @default.
• W3164172015 hasAuthorship W3164172015A5034266471 @default.
• W3164172015 hasAuthorship W3164172015A5045325872 @default.
• W3164172015 hasAuthorship W3164172015A5054685224 @default.
• W3164172015 hasAuthorship W3164172015A5055302708 @default.
• W3164172015 hasAuthorship W3164172015A5061139474 @default.
• W3164172015 hasAuthorship W3164172015A5073627317 @default.
• W3164172015 hasAuthorship W3164172015A5079550885 @default.
• W3164172015 hasAuthorship W3164172015A5079946212 @default.
• W3164172015 hasAuthorship W3164172015A5080646462 @default.
• W3164172015 hasBestOaLocation W31641720151 @default.
• W3164172015 hasConcept C126322002 @default.
• W3164172015 hasConcept C134018914 @default.
• W3164172015 hasConcept C144301174 @default.
• W3164172015 hasConcept C151956035 @default.
• W3164172015 hasConcept C1862650 @default.
• W3164172015 hasConcept C188816634 @default.
• W3164172015 hasConcept C201903717 @default.
• W3164172015 hasConcept C2777575956 @default.
• W3164172015 hasConcept C2780221984 @default.
• W3164172015 hasConcept C2780586474 @default.
• W3164172015 hasConcept C38180746 @default.
• W3164172015 hasConcept C555293320 @default.
• W3164172015 hasConcept C71924100 @default.
• W3164172015 hasConcept C72563966 @default.
• W3164172015 hasConceptScore W3164172015C126322002 @default.
• W3164172015 hasConceptScore W3164172015C134018914 @default.
• W3164172015 hasConceptScore W3164172015C144301174 @default.
• W3164172015 hasConceptScore W3164172015C151956035 @default.
• W3164172015 hasConceptScore W3164172015C1862650 @default.
• W3164172015 hasConceptScore W3164172015C188816634 @default.
• W3164172015 hasConceptScore W3164172015C201903717 @default.
• W3164172015 hasConceptScore W3164172015C2777575956 @default.
• W3164172015 hasConceptScore W3164172015C2780221984 @default.
• W3164172015 hasConceptScore W3164172015C2780586474 @default.
• W3164172015 hasConceptScore W3164172015C38180746 @default.
• W3164172015 hasConceptScore W3164172015C555293320 @default.
• W3164172015 hasConceptScore W3164172015C71924100 @default.
• W3164172015 hasConceptScore W3164172015C72563966 @default.
• W3164172015 hasIssue "Suppl 1" @default.
• W3164172015 hasLocation W31641720151 @default.
• W3164172015 hasOpenAccess W3164172015 @default.
• W3164172015 hasPrimaryLocation W31641720151 @default.
• W3164172015 hasRelatedWork W2014344432 @default.
• W3164172015 hasRelatedWork W2093301149 @default.
• W3164172015 hasRelatedWork W2125349643 @default.
• W3164172015 hasRelatedWork W2125544055 @default.
• W3164172015 hasRelatedWork W2164379467 @default.
• W3164172015 hasRelatedWork W2324571418 @default.
• W3164172015 hasRelatedWork W2402943696 @default.
• W3164172015 hasRelatedWork W2486901907 @default.
• W3164172015 hasRelatedWork W2919701695 @default.
• W3164172015 hasRelatedWork W2926045204 @default.
• W3164172015 hasVolume "80" @default.
• W3164172015 isParatext "false" @default.
• W3164172015 isRetracted "false" @default.
• W3164172015 magId "3164172015" @default.
• W3164172015 workType "article" @default.